San Francisco, US. - IVI RMA North America, one of the world’s most influential fertility networks, has entered into ...

AI brings its own validation challenges. Unlike static assays, machine learning algorithms evolve as they ingest new data, meaning that performance can change after regulatory approval. This dynamic ...

Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoringMORRISVILLE, N.C.--(BUSINESS ...

HALIFAX, NOVA SCOTIA / ACCESS Newswire / November 28, 2025 / MedMira Inc. (MedMira) (TSXV:MIR), reported today on its financial results for the financial year ended July 31, 2025. Corporate update In ...

SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five ...

Overture Life, the global leader in automated IVF and the first company to achieve live births from both robotic fertilization and robotic egg freezing, announced that the company ...

DaVitri becomes the first automated device cleared in the EU or U.S. for the vitrification of unfertilized eggs and the first freezing system approved with a blastocyst-rate performance claim ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced that three abstracts will be presented at the San Antonio Breast Cancer ...

With its European and Chinese partners, Kiwi drug minnow AFT Pharmaceuticals plans a 1000-patient trial of a novel iron ...

"The Prostate Cancer iPRS test elevates risk assessment in men's health," said Dr. Akash Kumar, co-founder of MyOme. "By integrating genome sequencing with clinical risk factors, we can more precisely ...

Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical trial, a key milestone in the company's efforts to bring a targeted next-generation sequencing solution ...

(Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today shared its growth vision under the bitXbio™ strategy. bitXbio™ (pronounced ...